Month: November 2021
—Selective targeting of IL-2, a potent immunomodulator, to CD8+ T cells results in enhanced anti-tumor activity across multiple in vivo animal models and an enhanced safety profile — — IND filing for AB248 on-track for 3Q 2022 — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-directed immunotherapies…
Read More
–Publication highlights first ever, most comprehensive data-driven neurobiological mapping of the mind– –Findings, published in Nature Neuroscience, validate Alto’s rigorous high-science approach and may be translated to future drug discovery and development– –Intellectual property has been exclusively licensed to Alto by Stanford– Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience today announced the publication of the…
Read More
Excerpt from the Press Release: Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function suggesting the platform can potentially be utilized to improve clinical CD19…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual…
Read More
Excerpt from the Press Release: Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting Early CUE-101 combination data with KEYTRUDA® (pembrolizumab) supports potential mechanistic activity CUE-102 in vivo data demonstrated ability to selectively activate and expand Wilms’…
Read More
“TrialStat’s Unified eClinical Suite supports clinical trials for pharmaceuticals, vaccines, and medical devices by helping to capture and analyze millions of records during each trial. With FlashArray//X, TrialStat software gains the speed and real-time data access that researchers need.” Read the case study to find out why TrialStat has partnered with PureStorage and how the…
Read More
ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin Lymphoma UNIVERSAL Study Abstract Selected for Oral Presentation Reports Meaningful Activity of a…
Read More
New Data at TCT From the Disrupt CAD Clinical Program Demonstrate Consistency of Shockwave IVL Outcomes Over Time, Across Calcium Morphologies and Between Genders Excerpt from the Press Release: SANTA CLARA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely…
Read More
Bluestar Genomics Presents New Data Showing its Liquid Biopsy Test Detects Pancreatic Cancer Signal.
-Analytical performance data presented at the American Pancreatic Association meeting- -The company also appointed seasoned industry leader Jim Vaughn as its chief commercial officer- Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, an innovative company leading the development of next-generation liquid biopsy approaches to early cancer detection, today announced the presentation of new analytical…
Read More
Sustained decrease in proteinuria observed in subgroup of patients with systemic lupus erythematosus, without lupus nephritis, following two doses of itolizumab Dose dependent decreases in inflammatory marker CD6 following itolizumab administration Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory…
Read More